NADAC acquisition cost data for TRULICITY 1.5 MG/0.5 ML PEN. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
| 00002143480 | $425.63 | 2022-01-01 | Rx |
Generic: Dulaglutide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.3B | 2,138,442 | 392,939 | $381.47 |
| 2020 | $3.3B | 2,823,185 | 497,327 | $400.68 |
| 2021 | $4.7B | 3,704,201 | 663,858 | $432.43 |
| 2022 | $6.2B | 4,610,823 | 840,163 | $459.01 |
| 2023 | $7.4B | 5,316,020 | 938,731 | $483.21 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $579.9M | 425,850 | 75,607 |
| New York | $561.8M | 388,347 | 67,955 |
| Texas | $524.0M | 344,310 | 70,728 |
| Florida | $414.5M | 297,335 | 57,909 |
| Pennsylvania | $411.2M | 322,930 | 52,807 |
| Ohio | $367.9M | 270,269 | 48,550 |
| Michigan | $346.7M | 246,740 | 47,342 |
| Massachusetts | $309.3M | 233,034 | 38,753 |
| Illinois | $238.3M | 168,513 | 31,715 |
| North Carolina | $237.1M | 181,683 | 32,333 |
| Georgia | $208.5M | 145,271 | 27,402 |
| Indiana | $184.9M | 130,080 | 24,319 |
| Wisconsin | $174.4M | 130,622 | 22,095 |
| New Jersey | $168.8M | 110,320 | 21,378 |
| Virginia | $168.2M | 128,090 | 23,377 |
| Tennessee | $164.5M | 118,349 | 22,659 |
| Louisiana | $146.8M | 114,632 | 20,045 |
| Missouri | $146.0M | 109,997 | 19,898 |
| Arizona | $142.8M | 93,715 | 19,646 |
| Alabama | $134.1M | 101,928 | 18,849 |
| South Carolina | $128.3M | 92,051 | 17,552 |
| Kentucky | $118.8M | 85,506 | 15,920 |
| Maryland | $118.3M | 75,798 | 15,344 |
| Minnesota | $98.9M | 68,637 | 12,485 |
| Washington | $95.9M | 67,141 | 12,905 |
| Oklahoma | $93.3M | 70,753 | 12,960 |
| Colorado | $92.7M | 62,727 | 12,200 |
| Connecticut | $84.6M | 56,912 | 10,670 |
| Oregon | $73.3M | 52,640 | 9,813 |
| West Virginia | $65.2M | 46,261 | 8,503 |
| Mississippi | $58.3M | 44,619 | 8,205 |
| Iowa | $57.5M | 46,894 | 7,433 |
| Kansas | $56.3M | 44,384 | 7,321 |
| New Mexico | $54.0M | 38,478 | 7,294 |
| Puerto Rico | $53.2M | 49,723 | 7,043 |
| Arkansas | $53.2M | 41,848 | 7,209 |
| Nevada | $50.5M | 32,405 | 6,814 |
| Maine | $50.0M | 33,201 | 6,229 |
| Utah | $47.7M | 36,002 | 6,782 |
| Nebraska | $40.5M | 33,364 | 5,287 |
| Idaho | $37.5M | 27,846 | 5,083 |
| New Hampshire | $32.9M | 22,857 | 4,516 |
| Delaware | $30.4M | 17,771 | 3,906 |
| Rhode Island | $25.4M | 21,685 | 3,676 |
| Hawaii | $22.5M | 14,044 | 2,896 |
| Montana | $17.6M | 13,510 | 2,338 |
| Vermont | $16.1M | 11,626 | 2,040 |
| District of Columbia | $15.6M | 10,759 | 2,185 |
| South Dakota | $12.0M | 9,042 | 1,586 |
| North Dakota | $10.8M | 8,911 | 1,431 |
| Alaska | $9.2M | 5,966 | 1,225 |
| Wyoming | $7.7M | 6,057 | 1,021 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.